MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 202200 | Name: Pelitrexol
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pelitrexol is a GARFT inhibitor, and is also a water soluble antifolate with anti-proliferative activity. Pelitrexol inhibits activity of glycinamide ribonucleotide formyltransferase (GARFT), the first folate-dependent enzyme of the de novo purine synthesis pathway essential for cell proliferation. Enzyme inhibition reduces the purine nucleotides pool required for DNA replication and RNA transcription. As a result, this agent causes cell cycle arrest in S-phase, and ultimately inhibits tumor cell proliferation.

Chemical Structure

Pelitrexol
Pelitrexol
CAS#446022-33-9

Theoretical Analysis

MedKoo Cat#: 202200

Name: Pelitrexol

CAS#: 446022-33-9

Chemical Formula: C20H25N5O6S

Exact Mass: 463.1526

Molecular Weight: 463.51

Elemental Analysis: C, 51.83; H, 5.44; N, 15.11; O, 20.71; S, 6.92

Price and Availability

Size Price Availability Quantity
2mg USD 210.00 Ready to ship
5mg USD 450.00 Ready to ship
10mg USD 650.00 Ready to ship
25mg USD 950.00 Ready to ship
50mg USD 1,650.00 Ready to ship
100mg USD 2,850.00 Ready to ship
Show More
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
AG-2037; AG 2037; AG2037; Pelitrexol.
IUPAC/Chemical Name
(S)-2-(5-(2-((S)-2-amino-4-oxo-3,4,5,6,7,8-hexahydropyrido[2,3-d]pyrimidin-6-yl)ethyl)-4-methylthiophene-2-carboxamido)pentanedioic acid
InChi Key
QXOPTIPQEVJERB-JQWIXIFHSA-N
InChi Code
InChI=1S/C20H25N5O6S/c1-9-6-14(18(29)23-12(19(30)31)3-5-15(26)27)32-13(9)4-2-10-7-11-16(22-8-10)24-20(21)25-17(11)28/h6,10,12H,2-5,7-8H2,1H3,(H,23,29)(H,26,27)(H,30,31)(H4,21,22,24,25,28)/t10-,12-/m0/s1
SMILES Code
O=C(O)[C@@H](NC(C1=CC(C)=C(CC[C@H](CN2)CC3=C2N=C(N)NC3=O)S1)=O)CCC(O)=O
Appearance
white solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
   
Biological target:
Pelitrexol (AG 2037) is an inhibitor of glycinamide ribonucleotide formyltransferase (GARFT).
In vitro activity:
To further define the effect of AG2037 on Rheb function, myc-tagged Rheb was immunoprecipitated from HEK293T cells treated with AG2037 with a conformation-specific monoclonal antibody that selectively recognizes RhebGTP. The results showed that AG2037 treatment dramatically decreased the ratio of RhebGTP to total Rheb and concomitantly suppressed S6RP and S6K1 phosphorylation (Figure 5B). Again, supplementation of the culture medium with adenine or guanine abrogated the negative effect of AG2037 on RhebGTP abundance in these cells (Figure 5B). AG2037 treatment consistently led to an upward shift in Rheb mobility during SDS-PAGE (Figure 5A). Reference: Cell Rep. 2017 Jun 27;19(13):2665-2680. https://linkinghub.elsevier.com/retrieve/pii/S2211-1247(17)30685-X
In vivo activity:
Mice harboring established, subcutaneous A427 xenografts were treated with either vehicle or AG2037 via intraperitoneal injection. Tumor growth was markedly reduced in the drug-treated animals relative to the vehicle-treated controls (Figure 4E). Tumor growth was suppressed by 64% and 69% at the 10 mg/kg and 20 mg/kg dosage levels, respectively. In a parallel group of tumor-bearing mice, the effect of AG2037 (20 mg/kg) on mTORC1 signaling 24 hr was assessed after the last drug administration. Immunoblot analyses of excised tumor tissue extracts revealed that AG2037 administration profoundly inhibited mTORC1-dependent phosphorylation of S6K1, S6RP, and CAD (Figure 4F). Thus, inhibition of GARFT-dependent purine biosynthesis blocks mTORC1 functions in this tumor cell line under both tissue culture and in vivo growth conditions. Reference: Cell Rep. 2017 Jun 27;19(13):2665-2680. https://linkinghub.elsevier.com/retrieve/pii/S2211-1247(17)30685-X
Solvent mg/mL mM
Solubility
DMSO 25.0 53.90
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 463.51 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
1. Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, Jin G, Myers J, Abraham RT, Unsal-Kacmaz K. Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep. 2017 Jun 27;19(13):2665-2680. doi: 10.1016/j.celrep.2017.05.043. PMID: 28658616.
In vivo protocol:
1. Emmanuel N, Ragunathan S, Shan Q, Wang F, Giannakou A, Huser N, Jin G, Myers J, Abraham RT, Unsal-Kacmaz K. Purine Nucleotide Availability Regulates mTORC1 Activity through the Rheb GTPase. Cell Rep. 2017 Jun 27;19(13):2665-2680. doi: 10.1016/j.celrep.2017.05.043. PMID: 28658616.
 1. Frost, Gregory I.; Jiang, Ping; Thompson, Curtis B. Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions. PCT Int. Appl. (2009), 292 pp. CODEN: PIXXD2 WO 2009128917 A2 20091022 CAN 151:462825 AN 2009:1297488 2. Czarnik, Anthony W. Deuterium-enriched pelitrexol. U.S. Pat. Appl. Publ. (2009), 10pp. CODEN: USXXCO US 2009062316 A1 20090305 CAN 150:314122 AN 2009:270615 3. Habib, Nabil. Treatment of cancer and other diseases. PCT Int. Appl. (2007), 86pp. CODEN: PIXXD2 WO 2007064691 A1 20070607 CAN 147:46112 AN 2007:619578 4. Hu, Shanghui; Kelly, Sean; Lee, Steve; Tao, Junhua; Flahive, Erik. Efficient Chemoenzymatic Synthesis of Pelitrexol via Enzymic Differentiation of a Remote Stereocenter. Organic Letters (2006), 8(8), 1653-1655. CODEN: ORLEF7 ISSN:1523-7060. CAN 144:488917 AN 2006:283608 5. Denis, Louis J.; Compton, Linda D. Method using camptothecin compounds, pyrimidine derivatives, and antitumor agents for treating abnormal cell growth. U.S. Pat. Appl. Publ. (2005), 32 pp. CODEN: USXXCO US 2005272755 A1 20051208 CAN 144:17160 AN 2005:1294044 6. Yaffe, Michael B.; Clapperton, Julie A.; Manke, Isaac A.; Lowery, Drew M.; Ho, Timmy; Haire, Lesley F.; Smerdon, Stephen J. The x-ray crystal structure of BRCA1 tandem BRCT repeat and BACH1 phosphopeptide complex and methods and compositions for antitumor drug design. PCT Int. Appl. (2005), 360 pp. CODEN: PIXXD2 WO 2005115454 A2 20051208 CAN 144:46998 AN 2005:1290072 7. Melton, Roger; Atkinson, Anthony. Use of enzyme carboxypeptidase G for combating toxicity caused by an antifolate compound. PCT Int. Appl. (2005), 54 pp. CODEN: PIXXD2 WO 2005084695 A2 20050915 CAN 143:299139 AN 2005:1004581 8. Lacasse, Eric; McManus, Daniel. Human protein IAP (inhibitor of apoptosis protein) nucleobase oligomers, including dsRNA, shRNA, and siRNA, and their use for enhancing apoptosis in cancer therapy. PCT Int. Appl. (2005), 112 pp. CODEN: PIXXD2 WO 2005042558 A1 20050512 CAN 142:457053 AN 2005:409543 9. Lacasse, Eric; McManus, Daniel; Durkin, Jon P. Sequences of antisense IAP (inhibitor of apoptosis protein) oligomers and their use for treatment of proliferative diseases with a chemotherapeutic agent. PCT Int. Appl. (2005), 285 pp. CODEN: PIXXD2 WO 2005042030 A1 20050512 CAN 142:457052 AN 2005:409357 10. Lee, Margaret S.; Nichols, James M.; Zhang, Yanzhen; Keith, Curtis. Combinations of chlorpromazine compounds and antiproliferative drugs for the treatment of neoplasms. PCT Int. Appl. (2005), 65 pp. CODEN: PIXXD2 WO 2005027842 A2 20050331 CAN 142:349042 AN 2005:283298 11. Dovalsantos, Elena Zapata; Flahive, Erik Jon; Halden, Brian John; Mitchell, Mark Bryan; Notz, Wolfgang Reinhard Ludwig; Tian, Qingping; O'Neil-Sla Wecki, Stacy Ann. Convergant synthesis of a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor containing a methyl substituted thiophene core and a tetrahydropyrido[2,3-d]pyrimidine ring system and intermediates therefor. PCT Int. Appl. (2004), 36 pp. CODEN: PIXXD2 WO 2004113337 A1 20041229 CAN 142:94129 AN 2004:1154710 12. Martinez, Carlos Alberto; Notz, Wolfgang Reinhard Ludwig. Convergent asymmetric synthesis route to produce a key intermediate towards the synthesis of a glycinamide ribonucleotide formyl transferase (GARFT) inhibitor. PCT Int. Appl. (2004), 38 pp. CODEN: PIXXD2 WO 2004113328 A1 20041229 CAN 142:74839 AN 2004:1154701 13. Fotoohi, Kambiz; Jansen, Gerrit; Assaraf, Yehuda G.; Rothem, Lilah; Stark, Michal; Kathmann, Ietje; Gregorczyk, Jacek; Peters, Godefridus J.; Albertioni, Freidoun. Disparate mechanisms of antifolate resistance provoked by methotrexate and its metabolite 7-hydroxymethotrexate in leukemia cells: Implications for efficacy of methotrexate therapy. Blood (2004), 104(13), 4194-4201. CODEN: BLOOAW ISSN:0006-4971. CAN 142:169330 AN 2004:1121011 14. Carson, Dennis A.; Leoni, Lorenzo M. Compositions and methods for the detection, prognosis, and treatment of methylthioadenosine phosphorylase deficient cancers using antibodies. PCT Int. Appl. (2004), 82 pp. CODEN: PIXXD2 WO 2004074325 A2 20040902 CAN 141:239297 AN 2004:718572 15. Bronder, Julie L.; Moran, Richard G. A Defect in the p53 Response Pathway Induced by de Novo Purine Synthesis Inhibition. Journal of Biological Chemistry (2003), 278(49), 48861-48871. CODEN: JBCHA3 ISSN:0021-9258. CAN 140:35493 AN 2003:935783 16. Bloom, Laura Anne; Boritzki, Theordore James; Kung, Pei-Pei; Ogden, Richard Charles; Skalitzky, Donald James; Zehnder, Luke Raymond; Kuhn, Leslie Ann; Meng, Jerry Jialun. Combination therapies for treating methylthioadenosine phosphorylase deficient cells. PCT Int. Appl. (2003), 189 pp. CODEN: PIXXD2 WO 2003074083 A1 20030912 CAN 139:246208 AN 2003:719328 17: De Martino, J. K., & Boger, D. L. (2008). Glycinamide ribonucleotide transformylase (GAR TFase) as a target for cancer therapy. Drug Future, 33, 969-979.
Tran DH, Kim D, Kesavan R, Brown H, Dey T, Soflaee MH, Vu HS, Tasdogan A, Guo J, Bezwada D, Al Saad H, Cai F, Solmonson A, Rion H, Chabatya R, Merchant S, Manales NJ, Tcheuyap VT, Mulkey M, Mathews TP, Brugarolas J, Morrison SJ, Zhu H, DeBerardinis RJ, Hoxhaj G. De novo and salvage purine synthesis pathways across tissues and tumors. Cell. 2024 Jul 11;187(14):3602-3618.e20. doi: 10.1016/j.cell.2024.05.011. Epub 2024 May 31. PMID: 38823389; PMCID: PMC11246224.